Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Diseases of the Esophagus

Safety and Efficacy of Camrelizumab Combined With Radiotherapy as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MCMaohui ChenYHYizhou HuangCLChuanquan Lin

Discussion

Loading...

Member takes

Overview

Single-arm trial shows favorable major pathological remission in esophageal squamous cell carcinoma, indicating potential of immunotherapy.

Key Points

  • Camrelizumab combined with radiotherapy achieved a major pathological remission rate of 65%, indicating effectiveness.
  • The R0 resection rate was 90.1% among patients who underwent surgery, demonstrating good surgical outcomes.
  • Immune pneumonitis and renal insufficiency were noted in some patients, highlighting the need for monitoring adverse events.
  • Neoadjuvant therapy shows promise for treating locally advanced esophageal squamous cell carcinoma, potentially improving patient outcomes.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/68c23cf6b210217d6478b86ehttps://doi.org/10.1093/dote/doaf061.156
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1223. CAMRELIZUMAB AND CHEMOTHERAPY AS NEOADJUVANT TREATMENT FOR LOCALLYADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)A SINGLE-ARM, PHASE II TRIAL2025
  2. 2107. CAMRELIZUMAB AND LOW-DOSE RADIOTHERAPY WITH CONCURRENT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (NICE-RT STUDY): PRELIMINARY RESULTS2025
  3. 3Analysis of camrelizumab in neoadjuvant chemotherapy for esophageal cancer: A retrospective cohort study2025 · 1 citations
  4. 4287. CAMRELIZUMAB, PACLITAXEL AND NEDAPLATIN AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESPRIT): A PHASE II, SINGLE-ARM STUDY2025
  5. 5272. CAMRELIZUMAB, PACLITAXEL AND NEDAPLATIN AS CONVERSION THERAPY FOR LOCALLY ADVANCED/ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II, SINGLE-ARM STUDY2025